Fina BioSolutions Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Fina BioSolutions's estimated annual revenue is currently $1.6M per year.(i)
  • Fina BioSolutions's estimated revenue per employee is $155,000

Employee Data

  • Fina BioSolutions has 10 Employees.(i)
  • Fina BioSolutions grew their employee count by 0% last year.

Fina BioSolutions's People

NameTitleEmail/Phone
1
CEO and OwnerReveal Email/Phone
2
VPReveal Email/Phone
3
Research ChemistReveal Email/Phone
4
Senior Principal ScientistReveal Email/Phone
5
Associate ResearcherReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.3M2-60%N/AN/A
#2
$2.9M38-31%$17.5MN/A
#3
$2.9M38-33%$10.5MN/A
#4
$19.8M1280%$69.4MN/A
#5
$9.6M62-15%N/AN/A
#6
$1.4M90%N/AN/A
#7
$2.5M160%N/AN/A
#8
$7.4M480%N/AN/A
#9
$0.2M1-83%N/AN/A
#10
$1.7M1122%N/AN/A
Add Company

What Is Fina BioSolutions?

Fina Biosolutions LLC is a privately held research and development stage biotechnology company that discovers, develops, and collaborates to commercialize novel vaccine conjugates for prevention of life-threatening diseases. Fina has patented novel techniques to conjugate, purify, and manufacture conjugates using its proprietary chemistry to create complex conjugate vaccines. The technology is currently licensed by leading vaccine manufacturers in both Europe and Asia, including GlaxoSmithKline for marketed vaccines Synflorixâ„¢ Menitorixâ„¢, Nimenrixâ„¢, The Serum Institute of India Ltd., The Chengdu Institute of Biological Products and others. Fina Bosolutions also manufactures E. coli expressed CRM197 conjugate vaccine carrier portein. Fina BioSolutions also develops polymer based diagnostic reagents, amino dextran, and antibody dextran conjugates.

keywords:N/A

N/A

Total Funding

10

Number of Employees

$1.6M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.9M100%N/A
#2
$0.9M100%N/A
#3
$0.9M100%N/A
#4
$0.9M10-41%N/A
#5
$1.7M1122%N/A